Orvar Jonsson, MD
Advanced Heart Failure and Transplant Cardiology · Sioux Falls, SDNPI 1831302009
Payments from drug & device makers
Across 673 payments — averaging $2692.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$657K
- Endotronix, Inc.$609K
- Novartis$220K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$97K
- Bayer$76K
- Janssen Research & Development, LLC$63K
- plus $91K from 22 others
What the payments were for
- Consulting fees$11,9608%
- Speaking & faculty fees$104,89974%
- Travel & lodging$9,8507%
- Food & beverage$15,04311%
- Education$1220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 224 | $656,689 |
| Endotronix, Inc. | 11 | $608,831 |
| Novartis | 62 | $220,407 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 51 | $96,529 |
| Bayer | 33 | $75,663 |
| Janssen Research & Development, LLC | 23 | $63,330 |
| Actelion Pharmaceuticals US, Inc. | 62 | $49,639 |
| Boehringer Ingelheim International GmbH | 64 | $18,450 |
| AstraZeneca | 15 | $9,612 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 3 | $7,624 |
| Cvrx, Inc. | 21 | $3,005 |
| Abiomed | 12 | $931 |
| Johnson & Johnson | 40 | $305 |
| E.r. Squibb & Sons, L.L.C. | 18 | $232 |
| United Therapeutics Corporation | 12 | $157 |
| Heartflow, Inc. | 1 | $130 |
| ZOLL Respicardia, Inc. | 1 | $112 |
| Impulse Dynamics (USA) Inc. | 3 | $66 |
| Chiesi USA, Inc. | 4 | $50 |
| Merck | 2 | $42 |
| Pfizer | 2 | $42 |
| Boehringer Ingelheim | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Cardiac Dimensions, Inc. | 1 | $26 |
| CSL Behring | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$48,571
- UPTRAVI$48,571
- ENTRESTO$48,435
- CARDIOMEMS$9,766
- FARXIGA$9,438
- CardioMEMS HF System$5,999
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$4,395
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$3,630
- Barostim Neo System$2,538
- HeartMate II LVAS$602
- Impella$139
- HeartMate Touch$134
- FFRct$130
- CentriMag$117
- AMPLATZER AMULET$114
- remede System$112
- HeartMate 3 Left Ventricular Assist Device$109
How this compares
Too few advanced heart failure and transplant cardiology providers in South Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 108 | $1,341,402 |
| Tyvaso DpiTreprostinil | 39 | $895,687 |
| UptraviSelexipag | 28 | $654,980 |
| EliquisApixaban | 459 | $310,544 |
| AdempasRiociguat | 17 | $220,920 |
| EntrestoSacubitril/Valsartan | 100 | $80,606 |
| XareltoRivaroxaban | 93 | $77,338 |
| Repatha SureclickEvolocumab | 87 | $56,141 |
| Ambrisentan | 13 | $37,050 |
| JardianceEmpagliflozin | 46 | $30,718 |
| Praluent PenAlirocumab | 42 | $24,177 |
| Repatha SyringeEvolocumab | 15 | $15,041 |
| BrilintaTicagrelor | 24 | $13,161 |
| FarxigaDapagliflozin Propanediol | 15 | $10,995 |
| Flecainide Acetate | 156 | $6,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $49,639 | $1,996,383136 claims |
| PfizerEliquis | $42 | $310,544459 claims |
| BayerAdempas | $75,663 | $220,92017 claims |
| NovartisEntresto | $220,407 | $80,606100 claims |
| Johnson & JohnsonXarelto | $305 | $77,33893 claims |
| Boehringer IngelheimJardiance | $33 | $30,71846 claims |
| AstraZenecaBrilinta, Farxiga | $9,612 | $24,15639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in South Dakotaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Sioux Falls
- Fnu Ayesha AzmeenSioux Falls$1K
- Luis Hernandez MejiaRapid City$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.